may delivered a positive earnings surprise GlycoMimetics (NASDAQ:GLYC)

0
11

Earnings results for GlycoMimetics (NASDAQ:GLYC)

Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingJun 2020 , the consensus EPS* forecast has remained the same over the past week at -0.37 and remained the same over the past month at -0.37. none raised and none lowered their forecast. For the fiscal year ending Dec 2020 , the consensus EPS* forecast has remained the same over the past week at -1.39 and remained the same over the past month at -1.39 . none raised and none lowered their forecast.

GlycoMimetics last issued its quarterly earnings data on May 1st, 2020. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.12. The business had revenue of $9 million for the quarter. GlycoMimetics has generated ($1.34) earnings per share over the last year. GlycoMimetics has confirmed that its next quarterly earnings report will be published on Friday, July 31st, 2020. GlycoMimetics will be holding an earnings conference call on Friday, July 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Analyst Opinion on GlycoMimetics (NASDAQ:GLYC)

6 Wall Street analysts have issued ratings and price targets for GlycoMimetics in the last 12 months. Their average twelve-month price target is $8.75, suggesting that the stock has a possible upside of 103.96%. The high price target for GLYC is $16.00 and the low price target for GLYC is $5.00. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”

GlycoMimetics has received a consensus rating of Buy. The company’s average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings. According to analysts’ consensus price target of $8.75, GlycoMimetics has a potential upside of 104.0% from its current price of $4.29. GlycoMimetics has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics does not currently pay a dividend. GlycoMimetics does not have a long track record of dividend growth.

Insiders buying/selling: GlycoMimetics (NASDAQ:GLYC)

In the past three months, GlycoMimetics insiders have not sold or bought any company stock. Only 26.80% of the stock of GlycoMimetics is held by insiders. 91.04% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of GlycoMimetics (NASDAQ:GLYC

Earnings for GlycoMimetics are expected to decrease in the coming year, from ($1.39) to ($1.64) per share. The P/E ratio of GlycoMimetics is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of GlycoMimetics is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. GlycoMimetics has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here